Anti-CD70 CAR-T cells
Phase 1Cell therapy
Anti-CD70 CAR-T cells is one of 4 biologic programs targeting Urologic Neoplasms. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Urologic Neoplasms
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Opdualag
Bristol-Myers SquibbPhase 2
Iparomlimab
TTianjin Medical University Cancer Institute and Hospital
Phase 2
Anti-CD70 CAR-T cells
SShanghai Changzheng Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Urologic Neoplasms1 trial
Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms
Recruiting·—·Phase 1·NCT05990621·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-CD70 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- SShanghai Changzheng Hospital